156 related articles for article (PubMed ID: 23181412)
1. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.
Porta C; Sabbatini R; Procopio G; Paglino C; Galligioni E; Ortega C
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1571-7. PubMed ID: 23181412
[TBL] [Abstract][Full Text] [Related]
2. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
3. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Calvo E; Ravaud A; Bellmunt J
Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
[TBL] [Abstract][Full Text] [Related]
4. [Systemic therapy for metastatic renal cell carcinoma].
Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
[TBL] [Abstract][Full Text] [Related]
5. Second-line systemic therapy for the treatment of metastatic renal cell cancer.
Kruck S; Bedke J; Kuczyk MA; Merseburger AS
Expert Rev Anticancer Ther; 2012 Jun; 12(6):777-85. PubMed ID: 22716494
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
7. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
[TBL] [Abstract][Full Text] [Related]
10. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
11. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
Coinu A; Petrelli F; Barni S
Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
14. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
15. Novel tyrosine kinase inhibitors for renal cell carcinoma.
Dorff TB; Pal SK; Quinn DI
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):67-73. PubMed ID: 24308791
[TBL] [Abstract][Full Text] [Related]
16. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
Eimer C; Gerullis H; Heuck C; Otto T
Anticancer Drugs; 2011 Jan; 22(1):18-23. PubMed ID: 21037468
[TBL] [Abstract][Full Text] [Related]
18. Second-line therapy for refractory renal-cell carcinoma.
Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
[TBL] [Abstract][Full Text] [Related]
19. Targeted agents for the treatment of advanced renal cell carcinoma.
Stadler WM
Cancer; 2005 Dec; 104(11):2323-33. PubMed ID: 16240452
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]